Pregabalin use extended

Lyrica (pregabalin) has been approved for the treatment of central neuropathic pain in adults, in addition to its previous licensed indication for the treatment of peripheral neuropathic pain in adults.

In the treatment of neuropathic pain, efficacy has been demonstrated in studies in diabetic neuropathy, post-herpetic neuralgia and spinal cord injury.

In a clinical trial involving patients with central neuropathic pain, 22% of patients treated with pregabalin showed a 50% improvement in pain score, compared to 7% in the placebo group.

The incidence of adverse events when treating central neuropathic pain due to spinal cord injury was increased.  This applied to general adverse events and CNS adverse events, particularly somnolence.

Lyrica is also indicated for the treatment of generalised anxiety disorder and adjunctive therapy in partial seizures.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Long-term antipsychotic use linked to breast cancer

Long-term antipsychotic use linked to breast cancer

Recent research indicates a significant increase in...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

SGLT2 inhibitors backed for cardiovascular prevention in draft NICE guidance

SGLT2 inhibitors backed for cardiovascular prevention in draft NICE guidance

SGLT2 inhibitors should be considered as first-line...